Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 3/20 | 0.49 |
| ▸ | CCKBR | P32239 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15989099 | 0.85 | LNPEP (0.47) | ERAP1LNPEPERAP2ITGA4ITGB7 | |
| SCHEMBL17403319 | 0.83 | LNPEP (0.53) | ERAP1LNPEPERAP2DHFRGPR132 | |
| SCHEMBL15989120 | 0.82 | GPR132 (0.58) | CCKARCCKBRACEERAP1LNPEP | |
| SCHEMBL18653960 | 0.81 | LNPEP (0.43) | CCKARLNPEP | |
| SCHEMBL15989164 | 0.81 | DHFR (0.48) | CCKARCCKBRACEERAP1LNPEP | |
| SCHEMBL18653995 | 0.81 | DHFR (0.48) | CCKARCCKBRACEERAP1LNPEP | |
| SCHEMBL15989075 | 0.79 | LNPEP (0.53) | ERAP1LNPEPERAP2DHFRGPR132 | |
| SCHEMBL18653875 | 0.79 | LNPEP (0.52) | ERAP1LNPEPERAP2GPR132 | |
| SCHEMBL15989069 | 0.79 | LNPEP (0.52) | ERAP1LNPEPERAP2GPR132 | |
| SCHEMBL15989169 | 0.78 | LNPEP (0.54) | ERAP1LNPEPERAP2GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9649373-B2 | Neoseptins: small molecule adjuvants | THE SCRIPPS INSTITUTE (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649373-B2 | Neoseptins: small molecule adjuvants | THE SCRIPPS INSTITUTE (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2958889-B1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | SCRIPPS RESEARCH INST (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | TLR2, TLR4, TLR1 | CCKAR 590/4885CCKBR 564/4885ACE 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.